drugset / Trial / NCT01843738
Radiation Use During Vemurafenib Treatment
NaSingle-groupOpen-labelTreatment
Summary
Patients are being asked to take part because they have melanoma that has spread to other organs in their body (metastatic). As part of this study, patients will receive radiation therapy and an approved drug (Vemurafenib).
Timeline
- Start
- 2017-06
- Primary completion
- 2022-08
- Completion
- 2022-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vemurafenib | Small molecule | 720 mg | Oral |
| Subject | Vemurafenib | Small molecule | 960 mg | Oral |